Quick Takeaways:
- Zoetis announced that Simparica Trio has received FDA Emergency Use Authorization (EUA) for the treatment of New World screwworm (NWS) larvae infestations in dogs and puppies. The authorization adds a new treatment option as NWS continues to pose a growing threat to animals in the U.S.
- New World screwworm larvae feed on living tissue, including open wounds, and can cause severe damage, pain and potentially death if untreated. Simparica Trio, already administered as a single monthly chew, provides protection against heartworm disease, six tick species, fleas, roundworms and hookworms, while preventing flea tapeworm infections.
- The EUA expands Zoetis’ multi-species response to NWS across companion animals and livestock, giving veterinarians another tool for managing infestations and added confidence to owners whose dogs already receive Simparica Trio. Zoetis encourages owners to consult veterinarians promptly if they notice suspicious wounds, maggots or possible infestations.
Why It Matters?
The FDA’s Emergency Use Authorization for Simparica Trio to treat New World screwworm (NWS) larvae in dogs gives veterinarians a convenient, oral option that can be used alongside existing livestock tools (e.g., Dectomax‑CA1) as part of a coordinated One Health response. Because Simparica Trio is already widely used as a monthly chew for heartworm, fleas, ticks and intestinal worms, the EUA can speed up treatment decisions in at‑risk areas (currently parts of Texas and New Mexico and for dogs traveling from affected regions), while reinforcing Zoetis’ multi‑species portfolio against NWS and supporting broader surveillance and control efforts.
Source: Businesswire
